Centessa Pharmaceuticals plc ADR [CNTA] stock is trading at $11.94, saw in change for the day. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CNTA shares have gain 11.48% over the last week, with a monthly amount drifted -30.58%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Centessa Pharmaceuticals plc ADR [NASDAQ: CNTA] stock has seen the most recent analyst activity on March 31, 2025, when Piper Sandler initiated its Overweight rating and assigned the stock a price target of $38. On September 20, 2024, upgrade upgraded it’s rating to Overweight and revised its price target to $26 on the stock. B. Riley Securities started tracking the stock assigning a Buy rating and suggested a price target of $33 on September 19, 2024. Oppenheimer initiated its recommendation with a Outperform and recommended $14 as its price target on July 18, 2024. Jefferies upgraded its rating to Buy for this stock on November 15, 2023, and upped its price target to $11. In a note dated October 26, 2023, Morgan Stanley upgraded an Equal-Weight rating on this stock and boosted its target price from $4 to $8.
Centessa Pharmaceuticals plc ADR [CNTA] stock has fluctuated between $7.75 and $19.09 over the past year. Currently, Wall Street analysts expect the stock to reach $27.5 within the next 12 months. Centessa Pharmaceuticals plc ADR [NASDAQ: CNTA] shares were valued at $11.94 at the most recent close of the market. An investor can expect a potential return of 130.32% based on the average CNTA price forecast.
Analyzing the CNTA fundamentals
Centessa Pharmaceuticals plc ADR [NASDAQ:CNTA] reported sales of 0.00M for the trailing twelve months, which represents a drop of -100.00%. To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -0.67 and Total Capital is -0.39. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.29.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.52 points at the first support level, and at 11.10 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.59, and for the 2nd resistance point, it is at 13.23.
Ratios To Look Out For
For context, Centessa Pharmaceuticals plc ADR’s Current Ratio is 9.25. Also, the Quick Ratio is 9.25, while the Cash Ratio stands at 6.61.
Transactions by insiders
Recent insider trading involved Weinhoff Gregory M, Chief Business Officer, that happened on Mar 25 ’25 when 10000.0 shares were sold. Officer, Weinhoff Gregory M completed a deal on Mar 25 ’25 to buy 10000.0 shares. Meanwhile, Chief Executive Officer SAHA SAURABH sold 55000.0 shares on Mar 20 ’25.
